サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1654668

胃運動障害治療薬の世界市場：2025年～2033年

Global Gastric Motility Disorder Drugs Market - 2025-2033

出版日
ページ情報
英文 176 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
胃運動障害治療薬の世界市場：2025年～2033年
出版日: 2025年02月13日
発行: DataM Intelligence
ページ情報: 英文 176 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の胃運動障害治療薬市場は、2024年に547億米ドルに達し、2033年には904億1,000万米ドルに達すると予測され、予測期間中の2025年から2033年のCAGRは5.0％で成長する見込みです。

胃運動障害とは、消化管（GI）を通る食物の正常な移動に影響を及ぼし、吐き気、嘔吐、腹部膨満感、便秘、腹痛などのさまざまな症状を引き起こす状態を指します。これらの疾患は、神経損傷、構造異常、消化管に影響を及ぼす感染症など、さまざまな原因によって生じます。

一般的な例としては、胃排出遅延を特徴とする胃不全麻痺や、明確な運動機能障害を伴わない上腹部の不快感を伴う機能性ディスペプシアなどがあります。これらの疾患は複雑であるため、患者のQOLに重大な影響を及ぼすことが多く、効果的な管理戦略が必要となります。プロキネティック剤（メトクロプラミドやドンペリドンなど）などの薬剤は、胃排出を促進し吐き気を緩和するために一般的に処方されます。

市場力学：

促進要因と抑制要因

胃運動障害の有病率の増加

胃運動障害の有病率の増加は、胃運動障害治療薬市場を大きく牽引するとみられます。胃不全麻痺や機能性ディスペプシアのような疾患の患者数が増加するにつれて、効果的な治療に対する需要も増加しています。例えば、2023年の国立衛生研究所の報告によると、機能性ディスペプシアは人口の20％以上が罹患する最も一般的な機能性胃腸障害の1つであると述べられています。

重症患者における消化管運動障害の発生率は約50％から80％です。このような患者数の増加は、新たな治療オプションの緊急の必要性を浮き彫りにするだけでなく、製薬会社の研究開発への投資を促し、それによって胃運動障害治療薬市場を拡大させています。したがって、上記の要因が予測期間中の市場成長を促進すると予想されます。

限られた治療薬

胃運動障害の治療薬の選択肢が限られていることは、市場の成長を大きく阻害する可能性があります。効果的で多様な治療選択肢がないため、患者のニーズが満たされておらず、その結果、有効性が不十分であったり副作用が重篤であったりする既存薬に頼ることになります。さらに、これらの疾患の根本的なメカニズムが不明確であるため、薬剤開発が複雑であることが、新たな治療法の導入をさらに制限し、最終的にこの分野の市場拡大と技術革新を阻害しています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 胃運動障害の有病率の増加
    • 抑制要因
      • 限られた治療薬
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 特許分析
  • 規制分析
  • SWOT分析
  • アンメットニーズ

第6章 薬剤タイプ別

  • 消化管運動促進剤
  • 副交感神経刺激薬
  • オピオイド拮抗薬
  • 下痢止め
  • 制吐薬
  • 抗生物質
  • その他

第7章 疾患タイプ別

  • アカラシア
  • 食道痙攣
  • 胸焼けまたは胃食道逆流症（GERD）
  • 胃不全麻痺
  • 過敏性腸症候群（IBS）
  • 便失禁
  • 腸閉塞
  • その他

第8章 流通チャネル別

  • 病院薬局
  • オンライン薬局
  • 小売薬局

第9章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州地域
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋
  • 中東・アフリカ

第10章 競合情勢

  • 競合シナリオ
  • 市況・シェア分析
  • M&A分析

第11章 企業プロファイル

  • Pfizer Inc.
    • 会社概要
    • 製品ポートフォリオ
      • 製品説明
      • 製品の主要業績評価指標（KPI）
      • 過去および予測の製品販売
      • 製品販売量
    • 財務概要
      • 会社の収益
      • 地域別収益分配
      • 収益予測
    • 主な発展
      • 合併と買収
      • 主な製品開発活動
      • 規制当局の承認等
    • SWOT分析
  • Eisai Co., Ltd.
  • Mallinckrodt
  • Salvus Pharma
  • Atmo Biosciences
  • AdvaCare Pharma
  • Avenacy
  • VAIKUNTH CHEMICALS PVT. LTD.
  • Healthy Inc
  • Bhumi Pharmaceuticals
  • Processa Pharmaceuticals, Inc.
    • パイプライン製品の説明
    • 製品の主要業績評価指標（KPI）
    • 主な活動
    • 市場参入のタイムライン
    • 製品普及率
    • 売上予測と予測
  • Vanda Pharmaceuticals Inc.
  • Renexxion Ireland Limited
  • Aclipse Therapeutics
  • 各市場参入企業に対しても同様のデータが提供されます。

第12章 付録

目次
Product Code: PH9104

The global gastric motility disorder drugs market reached US$ 54.7 billion in 2024 and is expected to reach US$ 90.41 billion by 2033, growing at a CAGR of 5.0% during the forecast period 2025-2033.

Gastric motility disorders refer to conditions that affect the normal movement of food through the gastrointestinal (GI) tract, leading to a range of symptoms such as nausea, vomiting, bloating, constipation, and abdominal pain. These disorders can arise from various causes, including nerve damage, structural abnormalities, or infections affecting the GI tract.

Common examples include gastroparesis, characterized by delayed gastric emptying, and functional dyspepsia, which involves discomfort in the upper abdomen without clear motor dysfunction. The complexity of these disorders often results in significant impacts on patients' quality of life, necessitating effective management strategies. Medications such as prokinetic agents (e.g., metoclopramide and domperidone) are commonly prescribed to enhance gastric emptying and alleviate nausea.

Market Dynamics: Drivers & Restraints

Increasing Prevalence of Gastric Motility Disorders

The increasing prevalence of gastric motility disorders is expected to significantly drive the gastric motility disorder drugs market. As the number of individuals with conditions such as gastroparesis and functional dyspepsia increases, the demand for effective treatments rises correspondingly. For instance, according to the report by the National Institute of Health in 2023, it was stated that functional dyspepsia is one of the most prevalent functional gastrointestinal disorders that affects over 20% of the population.

The occurrence of GI motility disorders approximates 50-80% in the critically ill patients. This growing patient population not only highlights the urgent need for new therapeutic options but also encourages pharmaceutical companies to invest in research and development, thereby expanding the market for gastric motility disorder drugs. Thus, the above factors are expected to drive the market growth during the forecast period.

Limited Drugs for Treatment

Limited drug options for treating gastric motility disorders can significantly hinder market growth. The lack of effective and diverse treatment alternatives leads to unmet patient needs, resulting in a reliance on existing medications that may have inadequate efficacy or severe side effects. Additionally, the complexity of drug development due to unclear underlying mechanisms of these disorders further restricts the introduction of new therapies, ultimately stifling market expansion and innovation in this sector.

Segment Analysis

The global gastric motility disorder drugs market is segmented based on drug type, disorder type, distribution channel, and region.

Drug Type:

Prokinetic agents segment is expected to dominate the global gastric motility disorder drugs market share

The prokinetic agents segment is poised to dominate the gastric motility disorder drugs market. This dominance is attributed to their effectiveness in alleviating various symptoms associated with gastroparesis by enhancing gastrointestinal motility and promoting gastric emptying. Prokinetic agents, such as metoclopramide and domperidone, are widely recognized for their ability to improve symptoms like nausea and bloating, making them essential in the management of gastric motility disorders.

With the growing demand for these drugs, companies are innovatively introducing these solutions to treat various gastric motility disorders. For instance, in September 2024, Avenacy launched Metoclopramide Injection, USP in the United States as a therapeutic generic equivalent for Reglan as approved by the U.S. Food and Drug Administration. Metoclopramide Injection, USP is indicated for the relief of symptoms associated with diabetic gastroparesis. Thus, the above factors are expected to hold the segment in the dominant position.

Geographical Analysis

North America is expected to hold a significant position in the global Gastric Motility Disorder Drugs market share

North America holds a major portion of the gastric motility disorder drugs market and is expected to dominate the market during the forecast period. This dominance is driven by several factors, including a high prevalence of gastric motility disorders, and significant investments in pharmaceutical research and development. The presence of major drug manufacturers in the region enhances innovation and access to advanced treatment options.

The region has a great regulatory framework supporting the entry of various innovative solutions. Several companies are initiating new clinical trials. For instance, in December 2023, The U.S. Food and Drug Administration (FDA) accepted the filing of Vanda Pharmaceuticals Inc.'s New Drug Application (NDA) for tradipitant for the treatment of symptoms of gastroparesis.

In April 2022, Processa Pharmaceuticals, Inc. announced that it enrolled its first patient in the Phase 2A clinical trial of PCS12852 in patients with moderate to severe gastroparesis. The above factors are expected to hold the region in the dominant position.

Competitive Landscape

The major global players in the gastric motility disorder drugs market include Pfizer Inc., Eisai Co., Ltd., Mallinckrodt, Salvus Pharma, Atmo Biosciences, AdvaCare Pharma, Avenacy, VAIKUNTH CHEMICALS PVT. LTD., Healthy Inc and Bhumi Pharmaceuticals among others.

Key Developments

  • In March 2024, Renexxion Ireland Limited announced that the U.S. Food and Drug Administration (FDA) has granted clearance for their Investigational New Drug (IND) application for naronapride. This drug is intended to treat patients suffering from gastroparesis, a condition characterized by delayed gastric emptying.
  • In September 2023, Aclipse Therapeutics and its subsidiary, Aclipse Two, Inc., announced the signing of an exclusive licensing agreement with Chong Kun Dang Pharmaceutical Corporation (CKD), based in Seoul, South Korea. This agreement grants Aclipse the worldwide rights (excluding South Korea, Indonesia, and Vietnam) to develop CKD's lobeglitazone for the treatment of gastroparesis and other potential indications.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Gastric Motility Disorder Drugs Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Drug Type
  • 3.2. Snippet by Disorder Type
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Prevalence of Gastric Motility Disorders
    • 4.1.2. Restraints
      • 4.1.2.1. Limited Drugs for Treatment
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Patent Analysis
  • 5.5. Regulatory Analysis
  • 5.6. SWOT Analysis
  • 5.7. Unmet Needs

6. By Drug Type

  • 6.1. Introduction
    • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 6.1.2. Market Attractiveness Index, By Drug Type
  • 6.2. Prokinetic Agents*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Parasympathomimetics
  • 6.4. Opioid Antagonists
  • 6.5. Antidiarrheals
  • 6.6. Anti-Emetic Drugs
  • 6.7. Antibiotics
  • 6.8. Others

7. By Disorder Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder Type
    • 7.1.2. Market Attractiveness Index, By Disorder Type
  • 7.2. Achalasia*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Esophageal spasms
  • 7.4. Heartburn or Gastroesophageal Reflux Disease (GERD)
  • 7.5. Gastroparesis
  • 7.6. Irritable Bowel Syndrome (IBS)
  • 7.7. Fecal incontinence
  • 7.8. Intestinal Pseudo-obstruction
  • 7.9. Others

8. By Distribution Channel

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 8.1.2. Market Attractiveness Index, By Distribution Channel
  • 8.2. Hospital Pharmacies*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder Type
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder Type
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. U.K.
      • 9.3.6.3. France
      • 9.3.6.4. Spain
      • 9.3.6.5. Italy
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder Type
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder Type
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. South Korea
      • 9.5.6.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder Type
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

Key Market Players

  • 11.1. Pfizer Inc.*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio
      • 11.1.2.1. Product Description
      • 11.1.2.2. Product Key Performance Indicators (KPIs)
      • 11.1.2.3. Historic and Forecasted Product Sales
      • 11.1.2.4. Product Sales Volume
    • 11.1.3. Financial Overview
      • 11.1.3.1. Company Revenue's
      • 11.1.3.2. Geographical Revenue Shares
      • 11.1.3.3. Revenue Forecasts
    • 11.1.4. Key Developments
      • 11.1.4.1. Mergers & Acquisitions
      • 11.1.4.2. Key Product Development Activities
      • 11.1.4.3. Regulatory Approvals etc.
    • 11.1.5. SWOT Analysis
  • 11.2. Eisai Co., Ltd.
  • 11.3. Mallinckrodt
  • 11.4. Salvus Pharma
  • 11.5. Atmo Biosciences
  • 11.6. AdvaCare Pharma
  • 11.7. Avenacy
  • 11.8. VAIKUNTH CHEMICALS PVT. LTD.
  • 11.9. Healthy Inc
  • 11.10. Bhumi Pharmaceuticals
  • Similar data will be provided for each market player.

Emerging Market Players

  • 11.11. Processa Pharmaceuticals, Inc.*
    • 11.11.1. Pipeline Products Description
    • 11.11.2. Product Key Performance Indicators (KPIs)
    • 11.11.3. Key Activities
    • 11.11.4. Market Entry Timelines
    • 11.11.5. Product Penetration Rate
    • 11.11.6. Sales Estimation and Projections
  • 11.12. Vanda Pharmaceuticals Inc.
  • 11.13. Renexxion Ireland Limited
  • 11.14. Aclipse Therapeutics
  • Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us